Literature DB >> 12817569

Molecular genetics of Alzheimer's disease: presenilin 1 gene analysis in a cohort of patients from the Poznań region.

Anna Kowalska1, Mieczyslaw Wender, Jolanta Florczak, Danuta Pruchnik-Wolinska, Renata Modestowicz, Józef Szczech, Grzegorz Rossa, Wojciech Kozubski.   

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by memory loss and personality changes. Pathological hallmarks of AD are: deposition of amyloid plaques and neurofibrillary tangles in the brain, accompanied by neuronal and synaptic loss. The genetic background of AD is heterogeneous and strongly depends on the form of the disease. In most of the families with early-onset AD (EOAD) (10% of the total population of patients), the disease segregates as an autosomal dominant fully penetrant trait. To date, some missense mutations in three genes encoding the amyloid precursor protein, presenilin 1 (PS1) and 2 (PS2) have been found to cause familial EOAD. We screened for mutations in the presenilin genes in a sample of 55 patients with familial or sporadic form of EOAD from the Poznan region. We found 4 missense mutations in the PS1 gene: A246E in exon 7, P267L in exon 8, E318G in exon 9, and L424R in exon 12 among 5 unrelated patients. The frequency of PS1 mutations was 11% (5 of 55) in the whole sample of the patients with EOAD or 50% (3 of 6) if the analysis was restricted to familial cases with a positive history of dementia in the patient's family.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12817569

Source DB:  PubMed          Journal:  J Appl Genet        ISSN: 1234-1983            Impact factor:   3.240


  7 in total

1.  Three novel presenilin 1 mutations marking the wide spectrum of age at onset and clinical patterns in familial Alzheimer's disease.

Authors:  Sigrun Roeber; Felix Müller-Sarnowski; Julia Kress; Dieter Edbauer; Tanja Kuhlmann; Frank Tüttelmann; Christoph Schindler; Pia Winter; Thomas Arzberger; Ulrich Müller; Adrian Danek; Hans A Kretzschmar
Journal:  J Neural Transm (Vienna)       Date:  2015-09-08       Impact factor: 3.575

2.  Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein.

Authors:  Oksana Berezovska; Alberto Lleo; Lauren D Herl; Matthew P Frosch; Edward A Stern; Brian J Bacskai; Bradley T Hyman
Journal:  J Neurosci       Date:  2005-03-16       Impact factor: 6.167

3.  Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database.

Authors:  John M Ringman; Sarah Monsell; Denise W Ng; Yan Zhou; Andy Nguyen; Giovanni Coppola; Victoria Van Berlo; Mario F Mendez; Spencer Tung; Sandra Weintraub; Marek-Marsel Mesulam; Eileen H Bigio; Darren R Gitelman; Amanda O Fisher-Hubbard; Roger L Albin; Harry V Vinters
Journal:  J Neuropathol Exp Neurol       Date:  2016-02-17       Impact factor: 3.685

Review 4.  Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene.

Authors:  A J Larner; M Doran
Journal:  J Neurol       Date:  2005-11-04       Impact factor: 6.682

5.  A Clinical Case of Patient Carrying Rare Pathological PSEN1 Gene Mutation (L424V) Demonstrates the Phenotypic Heterogenity of Early Onset Familial AD.

Authors:  Kaloyan R Stoychev; Maya Stoimenova-Popova; Petranka Chumpalova; Lilia Ilieva; Mohamed Swamad; Zornitsa Kamburova-Martinova
Journal:  Front Psychiatry       Date:  2019-12-11       Impact factor: 4.157

6.  Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors.

Authors:  Jill S Goldman; Susan E Hahn; Jennifer Williamson Catania; Susan LaRusse-Eckert; Melissa Barber Butson; Malia Rumbaugh; Michelle N Strecker; J Scott Roberts; Wylie Burke; Richard Mayeux; Thomas Bird
Journal:  Genet Med       Date:  2011-06       Impact factor: 8.822

Review 7.  The genetics of Alzheimer's disease.

Authors:  Eva Bagyinszky; Young Chul Youn; Seong Soo A An; SangYun Kim
Journal:  Clin Interv Aging       Date:  2014-04-01       Impact factor: 4.458

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.